Allogene Therapeutics ALLO Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's deferred tax assets and other non-current assets?
- Allogene Therapeutics (ALLO) reported deferred tax assets and other non-current assets of $3.53M in Q1 2026.
- How has Allogene Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- Allogene Therapeutics's deferred tax assets and other non-current assets increased by 85.8% year-over-year, from $1.9M to $3.53M.
- What is the long-term trend for Allogene Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Allogene Therapeutics's deferred tax assets and other non-current assets has grown at a -6.9% compound annual growth rate (CAGR), from $5.17M to $3.62M.